Skip to main content

Table 1 Expression of CLDN17 and the clinicopathological characteristics in HCC patients

From: Increased expression of claudin-17 promotes a malignant phenotype in hepatocyte via Tyk2/Stat3 signaling and is associated with poor prognosis in patients with hepatocellular carcinoma

Item n CLDN17 (+) CLDN17 (−) P
HCC tissues 52 28 24 < 0.01*
Hepatic tissues 30 12 18  
Age (years)
≤ 60 21 11 10 1.000
> 60 31 17 14  
HbsAg
+ 42 23 19 1.000
- 10 5 5  
Cirrhosis
+ 34 18 16 1.000
- 18 10 8  
Occurrence and metastasis
+ 17 13 4 < 0.01*
- 35 15 20  
Serum AFP (ng/ml)
 < 400 22 13 9 0.637
 > 400 30 15 15  
TNM stage (AJCC)
I~II 27 17 10 < 0.01*
III~IV 25 11 14  
Histological grade
Well-differentiated 24 15 9 < 0.01*
Moderately and poorly differentiated 28 13 15  
  1. *Statistical significance was found with the Chi-square test/Chi-Square Goodness-of-Fit Test